Protalix Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Protalix Biotherapeutics, Inc. on September 13, 2011. The filing serves as a Regulation FD disclosure regarding an upcoming corporate presentation.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report does not contain financial statements or performance metrics.
Material Changes
No material changes to financial position or operations are reported in this document. The filing solely announces a scheduled event.
Guidance, Outlook, and Management Commentary
Dr. David Aviezer, President and Chief Executive Officer, is scheduled to present at the UBS Global Life Sciences Conference on Tuesday, September 20, 2011, at 3:30 PM ET at the Grand Hyatt New York. The press release accompanying this filing is included as Exhibit 99.1. The information in this report is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Confirm the date and time of the UBS Global Life Sciences Conference presentation (September 20, 2011, 3:30 PM ET).
- Review the full text of the press release provided in Exhibit 99.1 for specific details on the presentation content.
- Note that this 8-K filing does not contain updated financial data or forward-looking guidance beyond the announcement of the event.